Table 4. The levels of PGE2, MMP-3, and Seprase in FLS among six groups after transfection (ng/L).
| Group | PGE2 | MMP-3 | Seprase |
|---|---|---|---|
| Control | 9.76 ± 2.15 | 185.84 ± 15.27 | 0.65 ± 0.08 |
| MiR-146a mimic | 3.21 ± 1.26* | 76.41 ± 16.32* | 0.31 ± 0.06* |
| MiR-146a inhibitor | 31.72 ± 1.53* | 391.75 ± 21.38* | 1.29 ± 0.07* |
| Tak-242 | 3.28 ± 1.19* | 77.68 ± 15.94* | 0.33 ± 0.05* |
| Mimic + LPS | 10.08 ± 2.38 | 187.62 ± 16.46 | 0.72 ± 0.13 |
| TLR4 | 47.45 ± 1.01*# | 54.11 ± 14.53*# | 7.49 ± 0.09*# |
Note: *P < 0.05 compared with the control group; #P < 0.05 compared with the miR-146a inhibitor group; miR-146a: microRNA-146a; MMP-3: matrix metalloproteinase-3; PGE-2: prostaglandin E2. The experiment was repeated for three times. Each group had four wells from different patients every time, and cell samples form 12 patients were used in the experiments.